Effect of Age on Efficacy and Safety of Once-Daily Single-Inhaler Triple Therapy Fluticasone Furoate/Umeclidinium/Vilanterol in Patients With Copd: A Post-Hoc Analysis of the Impact Trial

Abstract

Pharmacologic management of elderly patients with COPD may be affected by inability of patients to correctly use inhaler devices and concerns about overall benefit-risk of medications in this population relative to younger patients. We investigated effect of age on efficacy and safety of fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) 100/62.5/25mg vs FF/VI 100/25mg and UMEC/VI 62.5/25mg, all administered once daily via the Ellipta dry powder inhaler (DPI), in patients with COPD enrolled in the IMPACT trial.